Bio-Techne Tops Q2 Earnings & Revenue Estimates, Stock Up in Premarket
Bio-Techne TECH reported second-quarter fiscal 2025 adjusted earnings per share (EPS) of 42 cents, which exceeded the Zacks Consensus Estimate by 10.5%. The bottom line improved from the year-ago figure of 40 cents.
Bio-Techne Corporation (TECH) Q2 2025 Earnings Call Transcript
Good morning, and welcome to the Bio-Techne Earnings Conference Call for the Second Quarter of Fiscal Year 2025. At this time, all participants have been placed in a listen-only mode and the call will be open for questions following management's prepared remarks. During our Q&A session, please limit yourself to one question and one follow-up.
Bio-Techne Corp. Q2 Profit Increases, Beats Estimates
Bio-Techne Corp. (TECH) announced earnings for its second quarter that increased from last year and beat the Street estimates. The
Bio-Techne Fiscal Q2 Revenues up 9 Percent
The firm's Protein Sciences segment saw revenues increase 7 percent, while the Diagnostics and Spatial Biology segment's revenues rose 12 percent.
Bio-Techne Corporation: Bio-Techne Releases Second Quarter Fiscal 2025 Results
Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the second quarter ending December 31,
Bio-Techne beats Q2 earnings estimates on improving demand for biotech products
Bio-Techne beat second-quarter profit and revenue estimates on Wednesday, helped by growth in its protein sciences unit that makes products to develop therapies Shares of the company were up 6.8% in premarket trading.
Earnings call transcript: Bio-Techne beats Q2 2024 forecasts, stock surges
Bio-Techne Corp (NASDAQ:TECH) reported stronger-than-expected earnings for the second quarter of fiscal year 2024, with adjusted earnings per share (EPS) of $0.42, surpassing the forecasted $0.39. Revenue reached $297 million,
Bio-Techne Corp. stock underperforms Wednesday when compared to competitors despite daily gains
Shares of Bio-Techne Corp. TECH rose 3.72% to $75.25 Wednesday, on what proved to be an all-around favorable trading session ...
Bio-Techne (NASDAQ:TECH) Surprises With Strong Q4, Stock Soars
Life sciences company Bio-Techne (NASDAQ:TECH) reported Q4 CY2024 results topping the market’s revenue expectations, with ...
Bio-Techne signals high single-digit growth recovery by Q4 2025, driven by biopharma momentum
Q2 2025 Management View CEO Kim Kelderman highlighted 9% organic revenue growth for the quarter, driven by strong performance in biopharma end markets, particularly large pharma, which benefited GMP ...
Bio-Techne reports Q2 adjusted EPS 42c, consensus 38c
Reports Q2 revenue $297.03M, consensus $285.42M. “The Bio-Techne (TECH) team once again executed at a high level and delivered strong second ...
Bio-Techne Declares Dividend
Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended December 31, 2024. The quarterly dividend will be ...
Bio-Techne Co. (NASDAQ:TECH) Receives $82.00 Average Target Price from Brokerages
Shares of Bio-Techne Co. (NASDAQ:TECH – Get Free Report) have received a consensus recommendation of “Moderate Buy” from the eight ratings firms that are presently covering the stock, Marketbeat ...
Bio-Techne Corp. stock underperforms Monday when compared to competitors
Shares of Bio-Techne Corp. TECH shed 2.04% to $72.05 Monday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index SPX falling 0.76% to 5,994.57 and ...
Bio-Techne adds Dr. Amy E. Herr to its Board of Directors
Corporation (NASDAQ: TECH), a global life sciences company valued at $11.45 billion, has announced the appointment of Dr. Amy E. Herr as an independent director on its Board of Directors. Dr. Herr ...